Table 3 Feasible combination therapies in human clinical trials
From: Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy
Treatment regimens | Cancer type | Phase | Status | Locations | NCT |
|---|---|---|---|---|---|
ADU-S100 + Anti-PD antibody | Metastatic/Recurrent Head and Neck Cancer | II | Recruiting | United States | NCT03937141 |
ADU-S100 + Anti-PD antibody | Advanced/Metastatic Solid Tumors or Lymphomas | I | Active, not recruiting | United States | NCT02675439 |
MK-1454 + Pembrolizumab | Solid Tumors and Lymphoma | I | Recruiting | United States | NCT03010176 |
DMXAA + Taxane-based chemotherapies | Solid Tumor Malignancies | I | Terminated | United States | NCT01290380 |
DMXAA + Docetaxel | Advanced or Recurrent Solid Tumors | I | Completed | Japan | NCT01285453 |
DMXAA + Paclitaxel and Carboplatin | Non-Small Cell Lung Cancer | III | Terminated | United States | NCT00662597 |
DMXAA + Cetuximab | Refractory Solid Tumors | I | Withdrawn | United States | NCT01031212 |
DMXAA + Docetaxel | Urothelial Carcinoma | II | Withdrawn | United States | NCT01071928 |
DMXAA + Paclitaxel and Carboplatin | Non-Small Cell Lung Cancer | I | Completed | Japan | NCT00674102 |